This website is intended for people living with CF and their caregivers.
1_3_2_4_2

Vertex medicines

 

  • Please click here for KALYDECO® (ivacaftor) granules Package Leaflet or here for the Summary of Product Characteristics

  • Please click here for KALYDECO® (ivacaftor) tablets Package Leaflet or here for the Summary of Product Characteristics

  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) granules Package Leaflet or here for the Summary of Product Characteristics

  • Please click here for ORKAMBI® (lumacaftor/ivacaftor) tablets Package Leaflet or here for the Summary of Product Characteristics

  • Please click here for SYMKEVI® (tezacaftor/ivacaftor) Package Leaflet or here for the Summary of Product Characteristics

  • Please click here for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) granules Package Leaflet or here for the Summary of Product Characteristics

  • Please click here for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) tablets Package Leaflet or here for the Summary of Product Characteristics

ADVERSE EVENTS

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website www.hpra.ie, email: medsafety@hpra.ie. Side effects should also be reported to Vertex Pharmaceuticals (Ireland) Ltd 1800 924 568 or +353 (0)1 761 7299. By reporting side effects you can help provide more information on the safety of this medicine.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience. See information in paragraph above to see how to report side effects.